Comparison of the effect of cabergoline, letrozole and triptorelin on the treatment of uterine myomas: a randomized clinical trial

Phase 3

Conditions: terine myoma.
Leiomyoma of uterus, unspecified
D25.9

Registration Number: IRCT20211212053372N1

Lead Sponsor: Iran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Female

Target Recruitment: 75

Inclusion Criteria

20-45 years old women with uterine myoma (size 3 to 8 cm) presenting bleeding and pelvic pain.

Exclusion Criteria

Patients who have a hemoglobin level of 9 grams per deciliter or higher and consume iron pills.
Patients over the age of 45 years.
Patients with basal myoma who have received hormonal treatment in the past three months.
Patients with kidney and/or liver disease.
Consumers of antipsychotic drugs.
Patients with a history of drug treatment or surgery for uterine myoma with severe bleeding

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
terine size. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Sonography.;Uterine bleeding amount. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: menstrual cup.;Uterine myoma size. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Sonography.

Secondary Outcome Measures

Name	Time	Method
actate Dehydrogenase (LDH). Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Lactate Dehydrogenase (LDH) Assay Kit (Colorimetric).;Serum iron. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Serum Iron Assay Kit (Colorimetric).;Hemoglobin. Timepoint: At the beginning of the study (before the intervention) and three months later. Method of measurement: Hemiglobincyanide method.;Possible clinical side effects of the drug (Including hot flashes, headaches, vaginal dryness and vomiting, etc.). Timepoint: During and after 12 weeks of treatment. Method of measurement: Clinical examination.